Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Johnson & Johnson Seeks Approval for DARZALEX FASPRO as Monotherapy for Smoldering Multiple Myeloma

November 10, 2024
Johnson & Johnson has recently submitted applications in the U.S. and EU for the approval of DARZALEX FASPRO as a subcutaneous monotherapy for high-risk smoldering multiple myeloma. This move comes as part of the company's efforts to expand its portfolio in the oncology sector. DARZALEX FASPRO, a next-generation subcutaneous formulation of DARZALEX, has shown promising results in clinical trials, demonstrating its potential to improve outcomes for patients with this challenging condition. The submission of these applications marks a significant step forward in Johnson & Johnson's commitment to providing innovative treatment options for cancer patients. Investors are advised to consult with professionals from Stocks Prognosis for expert advice on the prospective movement of Johnson & Johnson's stocks.
If you want to leave a comment, then you need Login or Register





Other data for JNJ

Related data

JNJAugust 10, 2025Johnson & Johnson: How Investors May Respond To JNJ Talc Verdict and New Medical Innovations  ~1 min.

Johnson & Johnson, a global healthcare company, has recently been in the spotlight due to controversies surrounding their talc products....


JNJJuly 14, 2025Johnson & Johnson Innovates with New Product Launches  ~1 min.

Johnson & Johnson, a leading pharmaceutical company, continues to make waves in the industry with its latest submission of sNDA for the schizophrenia drug CAPLYTA to the FDA....


JNJMay 25, 2025Revolutionary Innovation: JNJ Johnson & Johnson Leads the Medical Industry with Groundbreaking Technology  ~1 min.

Johnson & Johnson, the renowned medical technology company, continues to be at the forefront of innovation in the industry....


JNJMarch 21, 2025Johnson & Johnson Neurovascular leader heads for the exit  ~1 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, has announced his departure from the company....


JNJMarch 20, 2025Johnson & Johnson Faces Shareholder Activism Over Human Rights and Executive Pay Proposals  ~2 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, is leaving the company, according to sources....


JNJMarch 19, 2025FDA Clears Johnson & Johnson Robot for Enhanced Bronchoscopy  ~1 min.

Johnson & Johnson's MedTech division has received clearance from the FDA for its enhanced robotic-assisted bronchoscopy system....


JNJMarch 18, 2025Johnson & Johnson MedTech Introduces New EP Neurovascular Leader  ~1 min.

Johnson & Johnson MedTech, a subsidiary of Johnson & Johnson, has appointed a new leader for its electrophysiology and neurovascular group....


JNJMarch 14, 2025Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments  ~1 min.

Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....


JNJFebruary 28, 2025Johnson & Johnson's Strong Performance Since Last Earnings Report Raises Expectations  ~1 min.

Johnson & Johnson (JNJ) has shown an impressive 8.9% increase in its stock price since the release of its last earnings report....


JNJFebruary 26, 2025The surgical devices I design for JJ speed healing and save lives  ~1 min.

Johnson & Johnson (JNJ) has been at the forefront of medical technology, constantly innovating and developing breakthrough surgical devices that not only speed up the healing process but also save lives....


JNJJanuary 28, 2025Johnson & Johnson's 2024 Fourth-Quarter and Full-Year Earnings Report Revealed  ~2 min.

Johnson & Johnson (JNJ) has released its highly anticipated earnings report for the fourth quarter and full-year of 2024....


PFEFebruary 28, 2025Pfizer Inc. PFE Announces Groundbreaking Cancer Treatment: Here is What You Should Know  ~2 min.

Pfizer Inc. PFE has recently made a groundbreaking announcement in the field of cancer treatment, attracting significant attention from investors....


GSKNovember 17, 2024GSK's Ojjaara Receives Health Canada Approval for Myelofibrosis in Anemia Patients  ~1 min.

GSK PLC, a leading pharmaceutical company, has received approval from Health Canada for its groundbreaking drug, Ojjaara, to be used in the treatment of myelofibrosis in anemia patients....


JNJJanuary 15, 2025JJ to buy psychiatric drug developer Intra-Cellular for 14.6B  ~2 min.

In a major move to bolster its presence in the mental health sector, pharmaceutical giant JNJ Johnson & Johnson has announced its acquisition of Intra-Cellular Therapies for a staggering $14.6 billion....


GSKJanuary 15, 2025GSK Acquires IDRx for 1B Gaining Breakthrough GIST Cancer Drug  ~2 min.

GSK PLC, a leading pharmaceutical company, has recently announced its acquisition of IDRx, a US-based biotech business, for a staggering amount of 1 billion dollars....